Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

INTRODUCTION: In a previously published study, vildagliptin showed a reduced risk of hypoglycemia versus glimepiride as add-on therapy to metformin at similar efficacy. Glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day. It is usually assumed that the increased h...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Ther
Autors principals: Ahrén, Bo, Foley, James Edward, Dejager, Sylvie, Akacha, Mouna, Shao, Qing, Heimann, Guenter, Dworak, Markus, Schweizer, Anja
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2014
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4269641/
https://ncbi.nlm.nih.gov/pubmed/25230877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-014-0082-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars